对赛义德·萨菲里和埃尔凡·阿尤比致编辑信的回复：关于尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等人的《肌肉浸润性膀胱癌患者保膀胱三联疗法的长期疗效：麻省总医院经验的最新分析》。《欧洲泌尿外科杂志》2017年；71卷：952 - 60页。避免误解的方法学问题。 - Suppr

Suppr

超能文献

Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation.

作者信息

Giacalone Nicholas J, Niemierko Andrzej, Shipley William U, Efstathiou Jason A

机构信息

Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Eur Urol. 2017 Sep;72(3):e64-e65. doi: 10.1016/j.eururo.2017.06.007. Epub 2017 Jun 19.

DOI:10.1016/j.eururo.2017.06.007

PMID:28642020

Abstract

摘要

相似文献

Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation.对赛义德·萨菲里和埃尔凡·阿尤比致编辑信的回复：关于尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等人的《肌肉浸润性膀胱癌患者保膀胱三联疗法的长期疗效：麻省总医院经验的最新分析》。《欧洲泌尿外科杂志》2017年；71卷：952 - 60页。避免误解的方法学问题。

Eur Urol. 2017 Sep;72(3):e64-e65. doi: 10.1016/j.eururo.2017.06.007. Epub 2017 Jun 19.

Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60: Methodological Issues to Avoid Misinterpretation.回复：尼古拉斯·J·贾卡洛内、威廉·U·希普利、丽贝卡·H·克莱曼等。肌肉浸润性膀胱癌患者膀胱保留三联疗法的长期疗效：麻省总医院经验的最新分析。《欧洲泌尿外科杂志》2017年；71:952 - 60：避免误解的方法学问题。

Eur Urol. 2017 Sep;72(3):e63. doi: 10.1016/j.eururo.2017.06.008. Epub 2017 Jun 23.

Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11.回复：杰森·A·埃夫斯塔西乌、达芙娜·Y·施皮格尔、威廉·U·希普利等。侵袭性膀胱癌综合治疗选择性膀胱保留的长期疗效：麻省总医院的经验。《欧洲泌尿外科杂志》2012年；61卷：705 - 11页

Eur Urol. 2012 Aug;62(2):e41; author reply e42. doi: 10.1016/j.eururo.2012.04.054. Epub 2012 May 8.

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.保留膀胱的三联疗法治疗肌层浸润性膀胱癌患者的长期疗效：马萨诸塞州综合医院经验的更新分析。

Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9.

Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013;63:823-9.回复：菲利普·J·格雷、斯泰西·A·费德瓦、威廉·U·希普利等人。美国肌肉浸润性膀胱癌的潜在治愈性疗法应用：来自国家癌症数据库的结果。《欧洲泌尿外科杂志》2013年；63卷：823 - 829页。

Eur Urol. 2013 Oct;64(4):e84-5. doi: 10.1016/j.eururo.2013.06.039. Epub 2013 Jul 2.

Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.对埃尔凡·阿尤比和赛义德·萨菲里致编辑的信的回复，主题为：R. 杰弗里·卡恩斯、沃莱克·乔恩、阿什利·E. 罗斯等人。用于预测具有不良病理特征男性前列腺癌特异性死亡率的基因组风险分类器的验证。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2017.03.036。方法学问题。

Eur Urol. 2017 Dec;72(6):e158-e159. doi: 10.1016/j.eururo.2017.05.030. Epub 2017 May 31.

Reply to Siebren Dijkstra and Carl J. Wijburg's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-71. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?

Eur Urol. 2019 May;75(5):e138-e139. doi: 10.1016/j.eururo.2019.01.037. Epub 2019 Feb 1.

Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18.回复桑塔南·桑达尔致编辑的信：关于阿尔努尔夫·施滕茨尔、奈杰尔·C·考恩、玛丽亚·德·桑蒂斯等人的《肌肉浸润性和转移性膀胱癌的治疗：欧洲泌尿外科学会指南更新》。《欧洲泌尿外科杂志》2011年；59卷：1009 - 1018页。

Eur Urol. 2012 Aug;62(2):e45-6. doi: 10.1016/j.eururo.2012.04.042. Epub 2012 May 3.

Reply to Samuel Bishara and Jim Adshead's letter to the editor re: Brian J. Linder, Igor Frank, John C. Cheville, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63:839-45.对塞缪尔·比沙拉和吉姆·阿兹海德致编辑信件的回复，内容涉及：布莱恩·J·林德、伊戈尔·弗兰克、约翰·C·切维尔等人的《围手术期输血对根治性膀胱切除术后癌症复发和生存的影响》。《欧洲泌尿外科杂志》2013年；63卷：839 - 45页

Eur Urol. 2013 Sep;64(3):e49-50. doi: 10.1016/j.eururo.2013.05.058. Epub 2013 Jun 12.

Re: J. Alfred Witjes, Thierry Lebret, Eva M. Compérat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.回复：J. 阿尔弗雷德·维特耶斯、蒂埃里·勒布雷、伊娃·M. 孔佩拉特等。《2016年欧洲泌尿外科学会肌肉浸润性和转移性膀胱癌指南更新》。《欧洲泌尿外科杂志》2017年；71卷：462 - 475页。

Eur Urol. 2017 Aug;72(2):e45. doi: 10.1016/j.eururo.2017.02.031. Epub 2017 Mar 6.

引用本文的文献

Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer.高级别非肌层浸润性膀胱癌和局限性肌层浸润性膀胱癌的膀胱保留现状

Curr Oncol Rep. 2025 Apr 30. doi: 10.1007/s11912-025-01657-3.

Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes.夹作为新型的基准标记物在三联疗法保膀胱治疗肌层浸润性膀胱癌中的应用：可行性和患者预后。

Int Braz J Urol. 2021 Jan-Feb;47(1):93-99. doi: 10.1590/S1677-5538.IBJU.2019.0713.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验